ESMO 2024: Pfizer’s Breakthrough in Cachexia Treatment
Monday, 16 September 2024, 06:13
Significant Findings on Ponsegromab
At ESMO 2024, Pfizer presented groundbreaking findings on Ponsegromab, a drug targeting cancer cachexia. Patients receiving the high dose experienced a clinically meaningful weight increase of 5.6%. This progress could revolutionize the management of cachexia, a condition often overlooked in cancer care.
Implications for Cancer Patients
- Weight gain can lead to improved treatment tolerance.
- Potentially enhances overall patient quality of life.
- Future studies expected to explore long-term effects.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.